Nirosha Mahendraratnam1,2, Joel F Farley3, Ethan Basch4,5, Amber Proctor6, Stephanie B Wheeler4,5, Stacie B Dusetzina7,8. 1. UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. nirosha.mahendraratnam@gmail.com. 2. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, CB# 7573, Chapel Hill, NC, 27599, USA. nirosha.mahendraratnam@gmail.com. 3. University of Minnesota College of Pharmacy, Minneapolis, MN, USA. 4. Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 5. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 6. UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 7. Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. 8. Vanderbilt University School of Medicine, Nashville, TN, USA.
Abstract
BACKGROUND: Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA. METHODS: Our study population was adult patients under the age of 65 with cancer initiating intravenous HEC between 2013 and 2015 with employer-sponsored insurance in the IBM Watson/Truven MarketScan Commercial Claims database (N = 31,923). Descriptive statistics were used to explain antiemetic prescribing patterns, including antiemetic underuse. Modified Poisson regression was used to identify factors associated with antiemetic underuse. RESULTS: Among individuals initiating HEC, 49% underused guideline-concordant antiemetics. Most classified as under-using lacked an NK1 fill. While dexamethasone and 5HT3A uptake was over 80%, olanzapine use was minimal. Having lower generosity for prescription and medical benefits (paying more versus less than 20% out-of-pocket) increased the underuse risk by 3% and 4% (RR,1.03; 95% CI,1.01-1.05; P = 0.01 and RR,1.04; CI, 1.00-1.09; P = 0.03), respectively. Additionally, compared to receiving chemotherapy in the physician office setting, patients were at a 28% (RR, 1.28; 95% CI, 1.25-1.30; P < 0.0001) higher underuse risk in the outpatient hospital setting. CONCLUSION: Antiemetic underuse is high in patients initiating HEC, potentially leading to avoidable CINV events. We found that insurance generosity has a minimal effect on antiemetic guideline concordance in this population, suggesting discordance may be the result of site of care as well as gaps in provider knowledge or accountability.
BACKGROUND:Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA. METHODS: Our study population was adult patients under the age of 65 with cancer initiating intravenous HEC between 2013 and 2015 with employer-sponsored insurance in the IBM Watson/Truven MarketScan Commercial Claims database (N = 31,923). Descriptive statistics were used to explain antiemetic prescribing patterns, including antiemetic underuse. Modified Poisson regression was used to identify factors associated with antiemetic underuse. RESULTS: Among individuals initiating HEC, 49% underused guideline-concordant antiemetics. Most classified as under-using lacked an NK1 fill. While dexamethasone and 5HT3A uptake was over 80%, olanzapine use was minimal. Having lower generosity for prescription and medical benefits (paying more versus less than 20% out-of-pocket) increased the underuse risk by 3% and 4% (RR,1.03; 95% CI,1.01-1.05; P = 0.01 and RR,1.04; CI, 1.00-1.09; P = 0.03), respectively. Additionally, compared to receiving chemotherapy in the physician office setting, patients were at a 28% (RR, 1.28; 95% CI, 1.25-1.30; P < 0.0001) higher underuse risk in the outpatient hospital setting. CONCLUSION: Antiemetic underuse is high in patients initiating HEC, potentially leading to avoidable CINV events. We found that insurance generosity has a minimal effect on antiemetic guideline concordance in this population, suggesting discordance may be the result of site of care as well as gaps in provider knowledge or accountability.
Entities:
Keywords:
Antiemetics; Chemotherapy-induced nausea and vomiting; Claims data; Clinical guidelines; Value-based care
Authors: Amin Haiderali; Laura Menditto; Margaret Good; April Teitelbaum; Jessica Wegner Journal: Support Care Cancer Date: 2010-06-09 Impact factor: 3.603
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman Journal: J Clin Oncol Date: 2017-07-31 Impact factor: 44.544
Authors: M Aapro; A Molassiotis; M Dicato; I Peláez; Á Rodríguez-Lescure; D Pastorelli; L Ma; T Burke; A Gu; P Gascon; F Roila Journal: Ann Oncol Date: 2012-03-06 Impact factor: 32.976
Authors: Jennifer L Malin; Jane C Weeks; Arnold L Potosky; Mark C Hornbrook; Nancy L Keating Journal: J Clin Oncol Date: 2012-12-26 Impact factor: 44.544
Authors: Arjun Gupta; Leonce Nshuti; Udhayvir S Grewal; Ramy Sedhom; Devon K Check; Helen M Parsons; Anne H Blaes; Beth A Virnig; Maryam B Lustberg; Ishwaria M Subbiah; Ryan D Nipp; Sydney M Dy; Stacie B Dusetzina Journal: JCO Oncol Pract Date: 2021-09-24